Call for Abstract
Scientific Program
International Conference on Pediatric Pharmacology and Therapeutics, will be organized around the theme “Unveiling the latest researches in pediatrics & connecting the global experts”
Pediatric Pharma 2018 is comprised of 13 tracks and 98 sessions designed to offer comprehensive sessions that address current issues in Pediatric Pharma 2018.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
- Track 1-1Approaches to pediatric studies
- Track 1-2PK only approach
- Track 1-3PK and PD approach
- Track 1-4PK and efficacy approach
- Track 1-5Safety, efficacy and potency considerations
- Track 2-1Pediatric diseases pathology
- Track 2-2Pediatric cardiac physiology
- Track 2-3Pediatric angina and treatments
- Track 2-4Pediatric antihypertensives
- Track 2-5ACE inhibitors for pediatrics
- Track 2-6Diuretics for children
- Track 3-1Adrenoleukodystrophy
- Track 3-2Alexander disease
- Track 3-3Leigh disease
- Track 3-4Rett syndrome
- Track 3-5Myoclonic astatic epilepsy
- Track 3-6Childhood disintegrative disorder
- Track 3-7Aicardi syndrome
- Track 3-8Asperger syndrome
- Track 3-9Canavan disease
- Track 3-10Lysosomal storage disease
- Track 3-11Pediatric movement disorders
- Track 3-12Cerebral palsy
- Track 3-13Epilepsy
- Track 3-14Autism
- Track 3-15Spinal cord injuries
- Track 3-16Traumatic brain injury
- Track 3-17Immune disorders
- Track 3-18Gene abnormalities
- Track 3-19Tardive dyskinesia
- Track 3-20Tourette syndrome
- Track 4-1Juvenile diabetes
- Track 4-2Hypothyroidism
- Track 4-3Hyperthyroidism
- Track 4-4Short stature
- Track 4-5Precocious puberty and delayed puberty
- Track 4-6Congenital Adrenal Hyperplasia (CAH)
- Track 4-7Turner Syndrome
- Track 5-1Gastric acid secretion
- Track 5-2H2 Anatagonists, PPIs and H.Pylori Therapy
- Track 5-3GI Motility Alterations- D2 Anagonist and 5HT4 Agonists
- Track 5-4Macrolides for children
- Track 5-5Diarrhoea and constipation in children
- Track 5-6Emesis and anti-emetic agents
- Track 5-7Irritable Bowel Syndrome treatment: spasmolytics, 5HT3 Anatgonists, 5HT4 Agonists
- Track 5-8IBD and anti-IBD therapies
- Track 6-1Chronic cough
- Track 6-2Difficulty breathing
- Track 6-3Recurring pneumonia
- Track 6-4Asthma
- Track 6-5Cystic fibrosis
- Track 6-6Apnea
- Track 6-7Chronic lung disease
- Track 6-8Noisy breathing
- Track 7-1juvenile rheumatoid arthritis
- Track 7-2Post-infectious arthritis
- Track 7-3Chronic musculoskeletal disorders
- Track 7-4Inflammatory disorders of the muscle
- Track 8-1Childhood leukemia
- Track 8-2Brain tumors
- Track 8-3Lymphomas
- Track 8-4Neuroblastoma
- Track 8-5Wilms tumor
- Track 8-6Non-Hodgkin lymphoma
- Track 8-7Childhood rhabdomyosarcoma
- Track 8-8Retinoblastoma
- Track 8-9Osteosarcoma
- Track 8-10Ewing sarcoma
- Track 8-11Germ cell tumors
- Track 8-12Pleuropulmonary blastoma
- Track 8-13Hepatoblastoma and hepatocellular carcinoma
- Track 9-1Acute liver failure
- Track 9-2Metabolic liver disease
- Track 9-3Billiary artresia
- Track 9-4Non-Alcoholic Fatty Liver Disease
- Track 10-1Elixirs
- Track 10-2Nipple shield delivery system
- Track 10-3Pill swallowing cups
- Track 10-4Orodispersible tablets (ODTs) and Orodispersible films (ODFs)
- Track 10-5Chewable formulations
- Track 10-6Inhalationals
- Track 11-1POPI: Pediatrics Omission of Prescriptions and Inappropriate Prescriptions
- Track 11-2Dose calculations
- Track 11-3Dosing instructions for children
- Track 11-4Overdose and sub-therapeutic dosing
- Track 11-5idiosyncratic reactions
- Track 11-6Adult dose extrapolations
- Track 12-1Therapeutic groups: vaccines, antibiotics and psychotropic medicines
- Track 12-2ADR symptoms- Rash, urticaria, fever, vomiting, chills, shock, rigor
- Track 12-3Skin and subcutaneous disorders
- Track 12-4General disorders
- Track 12-5Administration site conditions
- Track 12-6Gastrointestinal disorders
- Track 12-7Nervous system and psychiatric disorders
- Track 13-1 Food and Drug Administration Modernization Act
- Track 13-2Pediatric Research Equity Act
- Track 13-3BPCA: Best Pharmaceuticals for Children Act
- Track 13-4The Food and Drug Administration Safety and Innovation Act (FDASIA)